# A Phase II Study of BI-505 in Smoldering Multiple Myeloma

> **NCT01838369** · PHASE2 · TERMINATED · sponsor: **BioInvent International AB** · enrollment: 4 (actual)

## Conditions studied

- Smoldering Multiple Myeloma

## Interventions

- **DRUG:** BI-505

## Key facts

- **NCT ID:** NCT01838369
- **Lead sponsor:** BioInvent International AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-03
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Sponsor's decision
- **Last updated:** 2023-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01838369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01838369, "A Phase II Study of BI-505 in Smoldering Multiple Myeloma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01838369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*